Piscitelli Dominic sold $8K of ORIC

Piscitelli Dominic (Chief Financial Officer) sold 600 shares of Oric Pharmaceuticals, Inc. (ORIC) at an average of $13.50 ($13.50–$13.50) across 2 trades on 2026-09-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Piscitelli Dominic
Published Sep 25, 2026, 11:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 26, 2026, 12:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ORIC
Neutral
high confidence
Mentioned
$ORIC
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORICNeutralLow
01

Why it matters

The transaction is modest and unlikely to affect the stock materially.

02

Market read

Limited relevance; typical insider sale with minimal market impact.

03

What to watch

Potential upcoming corporate actions not disclosed

Relevance 2/10Novelty 4/10Timing: post‑market 2026‑09‑24

Background

Form 4 filing by Oric Pharmaceuticals CFO discloses a small open‑market sale under a pre‑arranged plan.

Company-level read

Ticker impact

$ORICNeutralHigh confidence
Context

CFO sold 600 shares for $8.1K via a 10b5‑1 plan on 2026‑09‑24

Expected impact

No material move expected

Evidence & confidence

Small insider sale by a senior officer, pre‑arranged plan, low dollar amount

Market effects

None

None

None

Counterpoint

Sale could be interpreted as lack of confidence, but 10b5‑1 plans are routine

Key entities

  • Oric Pharmaceuticals, Inc.

    US‑listed biotech (ticker ORIC)

  • Dominic Piscitelli

    Chief Financial Officer of Oric

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ORICMed

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

$ORICMedAI 8/10

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo